Zhang, Qi http://orcid.org/0000-0002-7918-8952
Riley-Gillis, Bridget
Han, Lina
Jia, Yannan
Lodi, Alessia
Zhang, Haijiao
Ganesan, Saravanan
Pan, Rongqing
Konoplev, Sergej N.
Sweeney, Shannon R.
Ryan, Jeremy A. http://orcid.org/0000-0002-3327-1283
Jitkova, Yulia
Dunner, Kenneth Jr
Grosskurth, Shaun E.
Vijay, Priyanka http://orcid.org/0000-0002-6032-9081
Ghosh, Sujana
Lu, Charles
Ma, Wencai
Kurtz, Stephen
Ruvolo, Vivian R.
Ma, Helen
Weng, Connie C.
Ramage, Cassandra L.
Baran, Natalia http://orcid.org/0000-0003-0618-4798
Shi, Ce
Cai, Tianyu
Davis, Richard Eric
Battula, Venkata L. http://orcid.org/0000-0001-5415-9058
Mi, Yingchang
Wang, Jing
DiNardo, Courtney D.
Andreeff, Michael http://orcid.org/0000-0002-1144-1958
Tyner, Jeffery W.
Schimmer, Aaron
Letai, Anthony http://orcid.org/0000-0002-1993-9013
Padua, Rose Ann
Bueso-Ramos, Carlos E.
Tiziani, Stefano
Leverson, Joel
Popovic, Relja
Konopleva, Marina
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA016672)
AbbVie
Article History
Received: 13 October 2020
Revised: 1 November 2021
Accepted: 20 December 2021
First Online: 21 February 2022
Change Date: 1 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41392-022-00958-4
Competing interests
: R.A.P. received financial support from AbbVie and Genentech. A.D.S. has received honorarium from Takeda, Novartis, Jazz, and Otsuka Pharmaceuticals and research support from Medivir AB and Takeda. A.D.S. is named as an inventor on a patent application related to the use of DNT cells in AML. A.D.S. owns stock in AbbVie Pharmaceuticals. A.D.S holds the Ronald N. Buick Chair in Oncology Research. MK: Consulting/honorarium: AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty-Seven, Kisoji; research funding/clinical trials support: AbbVie, Genentech, F. Hoffman La-Roche, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Agios, Ascentage, Astra Zeneca, Forty-Seven, Kisoji; stock options/royalties: Reata Pharmaceutical.